Physician profile
David E Cohen
NPI 1730179680
$2,961,968.29
in general payments reported to CMS, 2019-2025
25 companies · $56K in 2025
The $56K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175K · 2020: $166K · 2021: $2.4M · 2022: $36K · 2023: $64K · 2024: $104K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $185K · Travel and Lodging: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Honoraria: $10K · Food and Beverage: $3,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $184,809.62 |
| Travel and Lodging | $13,327.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,512.78 |
| Honoraria | $10,317.18 |
| Food and Beverage | $3,906.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kadmon Corporation LLC | $2,439,210.37 | 2019-2021 | |
| Leo Pharma INC. | $120,346.48 | 2020-2025 | Adbry |
| Dermira, INC. | $118,601.76 | 2019-2020 | |
| Leo Pharma As | $59,821.53 | 2019-2025 | Adbry |
| Ucb Sa | $49,952.04 | 2019-2025 | Bimzelx |
| Abbvie INC. | $45,495.43 | 2019-2024 | |
| Incyte Corporation | $22,920.83 | 2020-2025 | Opzelura |
| Amgen INC. | $22,823.65 | 2020-2025 | Enbrel, Enbrel |
| Pfizer INC. | $20,853.55 | 2019-2025 | |
| Janssen Global Services, LLC | $14,956.37 | 2020-2023 | Tremfya |
| Medimetriks Pharmaceuticals, INC. | $10,800.00 | 2019 | |
| Genzyme Corporation | $9,581.99 | 2019-2025 | |
| Ucb, INC. | $8,311.31 | 2020-2024 | Bimzelx, Cimzia |
| Lilly USA, LLC | $7,095.55 | 2019-2024 | Ebglyss |
| Novartis Pharmaceuticals Corporation | $4,445.00 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $2,900.30 | 2019 | |
| Janssen Biotech, INC. | $2,655.81 | 2025 | Tremfya |
| Dermavant Sciences, INC. | $422.79 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $418.59 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $109.67 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $108.07 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $61.50 | 2023 | Dupixent |
| Regeneron Pharmaceuticals, INC. | $38.30 | 2023 | |
| Galderma Laboratories, L.P. | $22.22 | 2025 | |
| Abbott Laboratories | $15.18 | 2025 | Diamondback Peripheral |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.